Renal failure is a major cause of morbidity and mortality in patients with multiple myeloma. At initial presentation, up to 50% of patients have renal impairment and 12 to 20% have acute renal failure; 10% become dialysis dependent (1–4). They represent 2% of the dialysis population (5) and there are approximately 5000 new patients, worldwide, each year (6). The major renal lesion is cast formation (cast nephropathy) in the distal tubules, which evolves to interstitial fibrosis (7,8). In these patients, large amounts of free light chains (FLC) readily pass through the glomerular fenestrations and overwhelm the absorptive capacity of the proximal tubules. On entering the distal tubules, they co-precipitate with Tamm-Horsfall protein to form waxy casts that both block the flow of urine and cause interstitial inflammation (7,9,10).
Studies have analyzed renal recovery rates after FLC removal by plasma exchange in multiple myeloma. This is a logical approach, but results have been disappointing. Although an early report was optimistic (11), the largest and most recent controlled trial (97 patients) showed no clinical benefit (12). A subsequent editorial in the Journal of the American Society of Nephrology listed the shortcomings of this study, including the failure to monitor either serum or urine FLC concentrations (13). It was noted, “This resembles antihypertensive treatment without measuring BP.” Clearly, the efficiency of plasma exchange for serum FLC removal could not be judged.
Winearls (14), in 1995, considered that plasma exchange was unlikely to remove sufficient FLC for clinical benefit. Because FLC are relatively small protein molecules (κ 25 kD and λ 50 kD), they are present in similar concentrations in serum, the extravascular compartment, and tissue edema fluid (15). Thus, the intravascular compartment may contain only 15 to 20% of the total amount. A series of 3.5-L plasma exchanges that removed only 65% of intravascular FLC on each occasion might have little overall impact, particularly if production were not reduced at the same time by chemotherapy.
An alternative approach is to remove FLC by hemodialysis (16). Although this is not possible with routine dialyzers (because of their small pores), a new generation of protein-leaking dialyzers, with very large pores, could be useful (17). By using extended dialysis, large amounts of FLC might be removed without the attendant clotting and deproteination problems that limit the extended use of plasma exchange. The aims of this study were to (1) make in vitro and in vivo assessments of several protein-leaking hemodialyzers, (2) develop a theoretical model for FLC removal, and (3) identify a clinical strategy for reduction of FLC in patients with multiple myeloma, with a view towards facilitating renal recovery.
Materials and Methods
This study was approved by the Solihull and South Birmingham Research Ethics Committees and the Research and Development Department of the University Hospitals Birmingham NHS Foundation Trust. All patients gave informed, oral and written consent.
Study Design and Participants
The study comprised (1) an initial in vitro and in vivo assessment of dialyzers for clearance of FLC, (2) development of a compartmental model for FLC removal on the basis of observed dialysis results, and (3) use of the model and the most efficient dialyzer to determine the optimal strategy for removal of FLC from patients with renal failure complicating multiple myeloma. The patients investigated were attending or referred to the nephrology department at the Queen Elizabeth Hospital.
In Vitro Assessment of FLC Removal by Isolated Ultrafiltration
Seven dialyzers were assessed for filtration efficiency (Table 1). Human serum, obtained from the Blood Transfusion Service, was spiked with 1000 mg of both monoclonal κ and λ FLC. Each dialyzer was placed in a simple circuit and primed with 1 L of normal saline. One liter of serum then was recirculated through the dialyzers at 400 ml/min, with transmembrane pressures of between 300 and 400 mmHg. The procedure was stopped when production of ultrafiltrate (UF) fluid ceased. The dialyzers finally were flushed with 1 L of fresh saline to remove fluid that contained any residual protein. The quantities of FLC in the filtered serum, UF, and flushed fluid were calculated from the FLC concentrations and measured volumes. Serum FLC reductions were calculated by subtraction of the final FLC concentrations from the initial values. The percentage of the original 1000 mg of each FLC, present in the UF at the end of the experiment, was calculated to determine the ability of the membrane to filter FLC. These assessments were repeated three times for each dialyzer, and the mean values were determined.
In Vitro Assessment of FLC Removal by Hemodialysis
The two dialyzers that filtered most FLC, the Toray BK-F 2.1 (Toray Industries Inc, Tokyo, Japan) and the Gambro HCO (high cutoff) 1100 (Gambro Dialysatoren GmbH, Hechingen, Germany), were assessed in vitro for dialysis efficiency. Each dialyzer was connected to a Gambro AK 90 hemodialysis machine and primed with 1 L of normal saline. One liter of human serum that contained 1000 mg of both κ and λ FLC then was dialyzed for 4 h. Serum flow rates were set at 300 ml/min, dialysate flow rates were set at 500 ml/min, and transmembrane pressures were set at 0 to 10 mmHg. Ultrafiltration rates of 0.05 and 0.25 L/h were used arbitrarily for the Gambro HCO 1100 and the Toray BK-F, respectively. Serum volumes were maintained at 1 L by an infusion of normal saline. After 2 h, the serum was spiked with 24 ml of saline that contained an additional 1000 mg of both κ and λ FLC to assess dialyzer blockage. Serum and dialysate fluids were sampled at short intervals for the FLC measurements (12 to 17 samples for each experimental part). Clearance values for κ and λ were calculated as follows (18):
Mean dialysate concentrations of FLC and clearance rates were calculated from both pre- and postspike samples, for both dialyzers and differences assessed.
In Vivo Assessment of FLC Removal in Patients with Multiple Myeloma
During the study period, 13 patients with dialysis-dependent renal failure (estimated GFR <15 ml/min per 1.73 m2) and multiple myeloma presented to the Nephrology Department. The first three patients underwent dialysis on one or more of the following dialyzers to determine their individual efficiency for FLC clearance: B. Braun Hi-PeS 18, (B. Braun Medical Ltd, Sheffield, UK) Toray BK-F 2.1, and Gambro HCO 1100. Subsequent patients underwent dialysis only on the Gambro HCO 1100 because of its superior FLC clearance rates (Tables 2 and 3). Patients 4 and 5 had routine dialysis for 4 h thrice weekly. Extended hemodialysis with the Gambro HCO dialyzer was evaluated in patients 6 through 8. Daily extended hemodialysis on the Gambro HCO dialyzer was evaluated for FLC removal in patients 9 through 13, who presented with cast nephropathy.
Serum and dialysate concentrations of FLC were measured at short intervals during the dialysis sessions. Percentage serum reductions in FLC, mean dialysate concentrations (mg/L), dialysate FLC content per hour of dialysis (g/h), and clearance rates (ml/min) were calculated. These results were compared for each membrane for the first three patients.
Evaluation of FLC Removal by Extended Hemodialysis on the Gambro HCO 1100
An extended dialysis regimen of up to 12 h was evaluated in eight patients (6–13) with dialysate flow rates of between 300 and 500 ml/min and blood flow rates of 150 to 250 ml/min. Some patients were treated with two or three dialyzers in series (Table 3). The following correlations were assessed: Serum FLC concentrations with quantity of FLC in the dialysate, serum reductions with duration of dialysis, clearance rates with dialysate flow rates, and dialyzer surface area. Cardiovascular stability was monitored throughout each dialysis session. Serum FLC, albumin, and electrolyte concentrations were measured before and after dialysis.
Therapeutic Extended Daily Hemodialysis on the Gambro HCO 1100 for Patients with Cast Nephropathy
During the study period, five patients (9 through 13) presented with new multiple myeloma, acute renal failure, and biopsy-proven cast nephropathy. An extended, daily dialysis regimen was undertaken in an attempt to reduce rapidly serum FLC concentrations. All patients received induction chemotherapy using local hematology protocols (Table 2). FLC clearance rates were evaluated with dialysate flow rates of between 300 and 500 ml/min and blood flow rates of 150 to 250 ml/min. Patients were assessed daily for determination of fluid balance with the aim of maintaining euvolemia. Ultrafiltration was used in addition to hemodialysis when there was fluid overload, and intravenous infusions were used to correct dehydration. Serum Ig were measured for assessment of immune status and normal human Ig were given, at 0.5 g/kg body wt, when serum IgG concentrations were <5 g/L.
Laboratory Measurements of FLC
Serum and dialysate κ and λ FLC concentrations were measured by nephelometry, on a Dade-Behring BNII Analyser, using a particle-enhanced, high-specificity, homogeneous immunoassay (FREELITE; The Binding Site, Birmingham, UK) (19). Normal serum reference ranges used were 7.3 mg/L (range 3.3 to 19.4) for κ and 12.7 mg/L (range 5.7 to 26.3) for λ with an assay sensitivity of <1 mg/L (20).
Mathematical Model of FLC Removal in Patients with Multiple Myeloma
A two-compartment mathematical model of FLC production, distribution, and removal in multiple myeloma was constructed to compare the efficiencies of plasma exchange and hemodialysis (Figure 1) (21). This was similar in structure to models for dialysis removal of urea and β2-microglobulin (22,23). It consisted of intravascular and extravascular compartments (one and two, respectively) with flow of FLC into, between, and out of each compartment (15). The renal clearance of serum FLC was considered zero (estimated GFR = 0) in patients with renal failure. Under such conditions, removal was by the reticuloendothelial system only, with a half-life of 3 d (24). With the use of this half-life, a production rate of 33.8 g/d produced a steady state of 10 g/L in the intravascular compartment. This was a convenient starting value for the clearance simulations.
Data from a patient with multiple myeloma were analyzed using the model within the software package Facsimile (25) to generate rates of serum FLC removal. Simulations then were conducted to compare six and 10 plasma exchange treatments (over 12 d) with five different hemodialysis protocols. Chemotherapeutic tumor killing rates of 0, 2, 5, and 10% per day and 100% on the first day were used (Table 4).
In vitro and in vivo studies of FLC removal by hemodialysis were compared using t test (two tailed, type 2) for significant differences. P < 0.05 was considered statistically significant.
In Vitro Assessment of FLC Removal by Isolated Ultrafiltration
The efficiencies of the various dialyzers for removal of FLC are shown in Table 1. All dialyzers caused substantial reductions of FLC concentrations in the circulated serum. Varying amounts of FLC were identified in UF, and it was assumed that the amounts missing were bound to the membranes. The Gambro HCO 1100 was the most efficient dialyzer; only small amounts of FLC bound to the membranes.
In Vitro Assessment of FLC Removal by Hemodialysis
The results for FLC removal by in vitro hemodialysis using the Toray BK-F 2.1 and the Gambro HCO 1100 dialyzers are shown in Table 5. Significantly higher FLC dialysate concentrations and greater serum reductions were achieved using the Gambro HCO dialyzer. Clearance rates of both FLC were 60-fold higher using the Gambro dialyzer compared with the Toray dialyzer.
In Vivo Use of Dialyzers for FLC Removal in Patients with Multiple Myeloma
The clinical details of patients who were studied for FLC removal are summarized in Table 2. All were in dialysis-dependent renal failure. FLC removal by hemodialysis was evaluated for three different dialyzers in the first three patients. Details of the dialysis periods and the amounts of FLC removed are shown in Table 3. For example, in patient 2, use of the Gambro HCO 1100 resulted in greater reductions in serum FLC concentrations (58.5%) than either the B. Braun Hi-Pes 18 (5.6%; P < 0.002) or the Toray BK-F 2.1 (24.2%; P < 0.001). The mean dialysate concentrations of FLC were many times higher during the dialysis sessions using the Gambro HCO 1100 (266 versus 5 mg/L using the B. Braun Hi-Pes 18 [P < 0.02] and 2 mg/L using the Toray BK-F 2.1 [P < 0.004]). Later patients (4 through 13) were treated only with the Gambro HCO 1100 dialyzer.
Evaluation of FLC Removal by Extended Hemodialysis on the Gambro HCO 1100
Extended hemodialysis (>4 h) on the Gambro HCO 1100 was evaluated for FLC removal in patients 6 through 13 (Table 3). The procedure was well tolerated with no cardiovascular complications. During sessions, there was a mean serum albumin reduction of 3.9 g/L (P < 0.03) that was replaced routinely with 20% albumin solution. Calcium and magnesium were replaced as required. Measurements indicated that there was no IgG leakage into the dialysate fluid.
The amounts of FLC in the dialysate fluids correlated with predialysis serum concentrations (R = 0.74, P < 0.0001). Figure 2 shows serum and dialysate FLC concentrations during a 6-h session for patient 6. When the dialyzer was replaced, there was a transient increase in FLC removal. Figures 3 through 5 show the daily pre- and postdialysis serum FLC concentrations and the amounts of FLC removed in the dialysate fluid (per 10-d periods) for patients 9 through 11, together with details of chemotherapy.
There was a significant correlation between percentage serum FLC reduction and the time on hemodialysis for all patients (R = 0.53, P < 0.001). Under similar conditions, mean clearance rates of FLC varied little between patients and correlated with dialysate flow rates (R = 0.58, P < 0.0001). The clearance was 10.8 ml/min at flow rates of 300 ml/min (range 5.2 to 22.6) and 19.3 ml/min (range 7.2 to 39.8) at 500 ml/min. Dialyzer surface area also was related to FLC clearance rates. For example, patient 10 was dialyzed on separate occasions on one, two, or three dialyzers, in series, with progressive increases in FLC clearance rates (Table 3 and Figure 6). The albumin loss in the dialysate increased significantly with each additional dialyzer (one: 0.16 g/L; two: 0.44 g/L; three: 0.58 g/L). In this patient, measurement of dialysate κ FLC concentrations during a 6-wk period indicated removal of 1.7 kg. Daily measurements of removal by hemodialysis and urine excretion plus estimated internal metabolism indicated a production rate of 150 to 200 g/d.
Therapeutic Extended Daily Hemodialysis on the Gambro HCO 1100 for Patients with Cast Nephropathy
During the study period, five unselected new patients presented with multiple myeloma and cast nephropathy (patients 9 through 13). All were dialysis dependent and were given dexamethasone-based induction chemotherapy. They were treated with an extended dialysis schedule of between 13 and 48 dialysis sessions, ranging from 2 to 12 h. Patients initially underwent dialysis on one dialyzer, for one or two sessions, and then two dialyzers in series. In the first week, they underwent dialysis on a daily basis and subsequently on alternate days. In all patients, extended hemodialysis resulted in large serum FLC reductions that were accounted for in the dialysate fluids (Table 3).
Three of the five patients became dialysis independent. Two patients (10 and 12) developed infections that prevented further use of chemotherapy. Although dialysis removed significant quantities of FLC, concentrations rebounded within 1 to 2 d and patients remained dialysis dependent. By contrast, the three patients who became dialysis independent (9, 11, and 13) responded well to chemotherapy, as evidenced by long-term reductions in serum FLC concentrations (Figures 3 and 5).
Simulation Model for FLC Removal
The results of the simulation studies are shown in Table 4 and Figure 7. With complete tumor killing on day 1 (simulation 1), serum FLC were >500 mg/L for 2 wk (assuming no therapeutic FLC removal). With a chemotherapeutic tumor kill rate of 10% per day and no dialysis, serum FLC concentrations remained >500 mg/L on day 30 (simulation 2). Plasma exchange (simulation 3) was less effective in reducing serum FLC than hemodialysis for 4 h three times per week using the Gambro HCO 1100 dialyzer (simulation 4), and neither method was rapid. Extended daily dialysis (for 12 h) reduced FLC concentrations to 5% of the starting concentrations in 5 d (simulation 6) compared with 29 d for plasma exchange (simulation 3). Analysis of the FLC load on the kidneys over 3 wk (area under the curves) showed that for simulation 3, 76% remained using plasma exchange and 11% remained after 5 d of 12 h/d hemodialysis (simulation 6), a 6.5-fold reduction. When chemotherapeutic killing rates were <10% per day, plasma exchange became progressively less effective than extended hemodialysis (Table 4). Ineffective chemotherapy, even with extended dialysis, did not normalize serum FLC concentrations (simulation 7).
The first aim of the study was to determine whether FLC could be cleared effectively by hemodialysis. Results from the initial, in vitro, ultrafiltration experiments suggested that several different dialyzers might be useful. For dialyzers with up to a 20-kD cutoff, protein recovery data indicated that membrane binding was the main clearance mechanism (Table 1). Subsequent in vitro and in vivo hemodialysis results demonstrated that the Gambro HCO 1100 dialyzer, with cutoff of 45 kD, was much more efficient than all others. Typically, serum FLC clearance rates of 10 to 40 ml/min were achieved, although filtration of both κ and λ molecules slowed with time. When dialyzers were replaced, FLC clearance increased slightly (Figure 2).
The amounts of serum FLC that were removed by hemodialysis were influenced by the initial serum FLC concentrations, time periods of dialysis, dialysis flow rates, and dialyzer surface area. The largest amounts removed were from patient 10, who had 42 g/L of serum κ FLC at clinical presentation. During a 6-week period, comprising 18 sessions of up to 10 h each, >1.7 kg of FLC was removed. For later dialysis sessions on this patient, two Gambro HCO 1100 dialyzers were connected in series. This added a convective element in addition to increasing the surface area, and the resulting FLC removal more than doubled. This occurred not only in the initial hour as the blood pool was reduced but also during the following hours, when the extravascular reservoir was partially cleared. After 4 to 5 h, serum FLC reductions slowed as the tumor production rate gradually was approached. As an alternative and perhaps more practical option, a single 2-m2 dialyzer could be used.
Although these studies did not assess specifically serum FLC removal by ultrafiltration, it probably would be effective. Figure 6 suggests that maximum clearance rates from the extravascular compartment were being approached with the use of two membranes in series, and there would have been a convective element. Further minor increases in FLC removal rates could be achieved by adjusting the blood or dialysis fluid flow rates. An additional factor that would cause variations in clearance rates between patients would be the degree of FLC polymerization, but this was not assessed (26).
Overall, the extended dialysis was well tolerated with no adverse effects. Previous studies showed the safe use of the Gambro HCO 1100 dialyzer in an intensive care setting (27,28). As predicted, we noted substantial albumin loss that required replacement on a regular basis (20 to 40 g per dialysis session and given as 20% human albumin solution). Such leakage is inevitable with a dialyzer that has a molecular cutoff of similar size to albumin (65 kD). Its use was not associated with hemodynamic or other adverse effects. Prophylactic antibiotics were given before invasive procedures and normal human Ig were used when serum IgG concentrations were <5 g/L. Patients with multiple myeloma usually are immunocompromised, so prevention of infections was important. Overall, our findings indicated that the Gambro HCO 1100 dialyzer was effective and safe when used for removal of huge amounts of monoclonal FLC.
The second aim of the study was to develop a theoretical model of FLC clearance for understanding of various treatment strategies. Using known variables for the model and patient data, we were able, on an iterative basis, to model FLC removal in vivo. This allowed calculation of possible FLC production rates, rates of movement between the extra- and intravascular compartments, and the effectiveness of hemodialysis to be compared with plasma exchange. When the model was interrogated for different treatment strategies, simulations indicated that 4 h of dialysis on alternate days (using the Gambro HCO 1100) compared favorably with recommended plasma exchange protocols (Figure 7 and Table 4) (12). The model indicated that 8 to 12 h of daily dialysis would reduce FLC to low serum concentrations within a few days, provided that chemotherapy was successful. We used a range of tumor killing rates in the model to include several clinical possibilities (Table 4). The 10 and 0% killing rates produced results that were in accordance with observed FLC responses for patient 9 (Figures 3 and 7) and for patient 10, respectively (Figures 4 and 7). There are no published reports of tumor killing rates for comparison, because multiple FLC measurements have not been made at this early stage of treatment. With less efficient tumor killing, the continuing FLC production rendered hemodialysis progressively more effective than plasma exchange (Table 4). More extensive plasma exchange regimens could have been evaluated, but five to seven procedures of 50 ml/kg over 10 to 12 d normally is recommended (12).
The accuracy and the reproducibility of the model requires further assessment, which is ongoing. However, it will always be a challenge to model renal FLC metabolism because it changes during renal recovery. Overall, it seemed that the model allowed reasonable comparison of different treatment regimens.
The third aim of the study was to identify a clinical strategy for reducing serum concentrations of FLC in multiple myeloma. Five consecutive patients with dialysis-dependent acute renal failure and biopsy-proven cast nephropathy were treated with extended daily hemodialysis, and three became dialysis independent. This compares with published figures of 15 to 20% in patients with biopsy-proven cast nephropathy (14,29). In these three patients, a reduction in serum FLC concentrations of 80 to 95% was associated with recovery of renal function. However, the toxicity of individual monoclonal FLC, the extent of underlying renal damage, and other clinical factors vary enormously, so more or less FLC removal may be appropriate in other patients. It is of note that the plasma exchange procedures that were assessed in the model (Table 4) and used in clinical practice (30) did not reduce serum FLC concentrations by even 30%.
The effectiveness of chemotherapy when treating these patients was of considerable importance. For example, in patient 9 (Figure 3), serum FLC reduced toward normal concentrations within 3 wk. Chemotherapy was effective, large amounts of FLC were removed, and renal function recovered. During the second course of dexamethasone, FLC concentrations reduced between dialysis periods. This probably was due to their metabolism and excretion by the kidneys and indicated recovering function. In patient 10 (Figure 4), chemotherapy was ineffective and then had to be stopped because of infections. Serum FLC concentrations were reduced temporarily by dialysis but rebounded within 1 to 2 d, and there was no renal recovery (Figure 4). It will be important to identify fast-acting and effective drug regimens that can be modified rapidly if FLC concentrations do not fall quickly. Combinations of bortezomib, doxorubicin, and dexamethasone or of cyclophosphamide, thalidomide, and dexamethasone are highly successful and have better response rates than vincristine, Adriamycin (doxorubicin), and dexamethasone (31).
It is possible that removal of FLC by hemodialysis can protect the kidneys from continuing damage for several weeks. Occasional reports have described late renal function recovery from cast nephropathy. For instance, two patients became dialysis independent after autologous bone marrow transplantation that was many months after their initial clinical presentation with acute renal failure (32). Serum FLC measurements were not reported, but we suggest that the use of high-dosage melphalan had stopped monoclonal FLC production. For renal recovery, however, effective tumor treatment to reduce FLC production is essential, in addition to any removal by hemodialysis. We have not removed FLC from patients who had less severe renal failure and did not require dialysis. Such patients also might benefit from this treatment.
For all patients, daily monitoring with serum FLC tests was helpful. The results made it possible to judge the ongoing effectiveness of the dialyzers and the chemotherapy. Such daily assessments are different from the typical management pace in myeloma. Treatment outcomes normally are assessed over weeks or months, largely from observations of the slow changes that are seen in serum IgG concentrations (half-life of 3 wk). FLC have serum half-lives from 2 to 3 h (2 to 3 d in renal failure), so clinical responses can be seen and acted on much more quickly (33,34).
Our results allow some interpretation of the plasma exchange study by Clark et al. (12), referred to earlier. Although there are no published results of serum FLC concentrations in relation to plasma exchange, a report in press (30) confirms model simulations that only 25 to 30% of the total amount typically is removed during a treatment period (Figure 7 and Table 4). Therefore, switching off FLC production by chemotherapy may have been the main determinant of renal recovery. Fewer than 40% of patients would have had a very good response to vincristine, Adriamycin (doxorubicin), and dexamethasone during the first few weeks of treatment (31). Their observed renal recovery rates of approximately 40% (in both plasma exchange and control groups) may reflect only such chemotherapy responses. Other causes of renal failure, such as acute tubular necrosis (as seen in one of our patients), also would be present, but renal biopsies were not performed. Without histologic clarification and frequent measurements of serum FLC, interpretation of trials that assess renal recovery in patients with myeloma kidney will prove difficult (13).
Our studies have demonstrated that daily, extended hemodialysis using the Gambro HCO 1100 dialyzer could remove continuously large quantities of FLC. Modeling and clinical data suggested that this was more effective than plasma exchange procedures. This is supported by early evidence of clinical efficacy, as judged by satisfactory renal recovery in three of five patients with cast nephropathy. Studies in more patients now are required with consideration given to optimal chemotherapy and infection control. It then might be appropriate to undertake controlled trials of hemodialysis using the Gambro HCO dialyzers to determine overall clinical utility.
This study was supported by The British Renal Society (grant 05-007).
We thank the patients, the nurses, and the physicians who contributed to this project, in particular Anne-Marie Phythian and Oliver Foster on the renal dialysis unit. We thank The Binding Site Ltd., for financial and technical support and the dialysis companies who supplied the dialyzers at no charge.
Some of these data were presented in abstract form at the annual meetings of the American Society of Hematology (Los Angeles, CA; December 9 to 12, 2006), the British Society of Hematology (Edinburgh, UK; April 3 to 5, 2006), the British Renal Association (Harrogate, UK; May 3 to 5, 2006), and the European Society of Artificial Organs (Umea, Sweden; June 21 to 24, 2006).
Published online ahead of print. Publication date available at www.jasn.org.
1. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson DR, Plevak ME, Therneau TM, Greipp PR: Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78 : 21 –33, 2003
2. Knudsen LM, Hjorth M, Hippe E: Renal failure in multiple myeloma: Reversibility and impact on prognosis. Eur J Haematol 65 : 175 –181, 2000
3. Gertz MA: Managing myeloma kidney. Ann Intern Med 143 : 835 –837, 2005
4. Blade J, Fernandez-Llama P, Bosch F, Montoliu J, Lens XM, Montoto S, Cases A, Darnell A, Rozman C, Montserrat E: Renal failure in multiple myeloma: Presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 158 : 1889 –1893, 1998
5. Iggo N, Winearls CG, Davies DR: Editorial: The development of cast nephropathy in multiple myeloma. Q J Med 90 : 653 –656, 1997
6. De Roos AJ, Baris D, Weiss NS, Herrinton L: Epidemiology of multiple myeloma. In: Myeloma: Biology and Management. 3rd Ed., edited by Malpas JS, Bergsagel DE, Kyle RA, Anderson KC, Philadelphia, Saunders, Elsevier, 2004 , pp 117 –157
7. Sanders PW, Brooker BB: Pathobiology of cast nephropathy from human Bence Jones proteins. J Clin Invest 89 : 630 –639, 1992
8. Herrera GA, Joseph L, Gu X, Hough A, Barlogie B: Renal pathologic spectrum in an autopsy series of patients with plasma cell dyscrasia. Arch Pathol Lab Med 128 : 875 –879, 2004
9. Sanders PW, Herrera GA, Kirk KA, Old CW, Galla JH: Spectrum of glomerular and tubulointerstitial renal lesions associated with monotypical immunoglobin light chain deposition. Lab invest 64 : 527 –537, 1991
10. Sanders PW: Renal involvement in plasma cell dyscrasias. Curr Opin Nephrol Hypertens 2 : 246 –252, 1993
11. Zucchelli P, Pasquali S, Cagnoli L, Ferrari G: Controlled plasma exchange trial in acute renal failure due to multiple myeloma. Kidney Int 33 : 1175 –1180, 1988
12. Clark WF, Stewart AK, Rock GA, Sternbach M, Sutton DM, Barrett BJ, Heidenheim AP, Garg AX, Churchill DN, Canadian Apheresis Group: Plasma exchange when myeloma presents as acute renal failure: A randomised controlled trial. Ann Intern Med 143 : 777 –784, 2005
13. Ritz E: Plasma exchange for acute renal failure of myeloma: Logical, yet ineffective. J Am Soc Nephrol 17 : 914 –916, 2006
14. Winearls CG: Acute myeloma kidney. Kidney Int 48 : 1347 –1361, 1995
15. Takagi K, Kin K, Itoh Y, Enomoto H, Kawai T: Human alpha 1-microglobulin in various body fluids. J Clin Pathol 33 : 786 –791, 1980
16. Bradwell AR, Evans ND, Chappell MJ, Cockwell P, Reid SD, Harrison J, Hutchison C, Mead GP: Rapid removal of free light chains from serum by hemodialysis for patients with myeloma kidney. Blood 106 : 972a , 2005
17. Ward RA: Protein-leaking membranes for hemodialysis: A new class of membranes in search of an application. J Am Soc Nephrol 16 : 2421 –2430, 2005
18. Lee WCR, Uchino S, Fealy N, Baldwin I, Panagiotopoulos S, Goehl H, Morgera S, Neumayer HH, Bellomo R: B2-microglobulin clearance with super high flux hemodialysis: An ex vivo study. Artif Kidney Dial 26 : 723 –727, 2003
19. Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT, Drew R: Highly sensitive automated immunoassay for immunoglobulin FLCs in serum and urine. Clin Chem 47 : 673 –680, 2001
20. Katzmann JA, Clark RJ, Abraham RS, Bryant S, Lymp JF, Bradwell AR, Kyle RA: Serum reference intervals and diagnostic ranges for free kappa and free gamma immunoglobulin light chains: Relative sensitivity for detection of monoclonal light chains. Clin Chem 48 : 1437 –1444, 2002
21. Evans ND, Hattersley J, Hutchison C, Hu Y, Godfrey KR, Bradwell AR, Mead GP, Chappell MJ: Modelling of hemodialysis in limiting serum free light chains in patients with renal failure. In: Proceedings of the 6th IFAC Symposium on Modelling and Control of Biomedical Systems, 2006 , in press
22. Depner TA: Prescribing Haemodialysis: Guide to Urea Modelling, Boston, Kluwer Academic Publishers, 1990
23. Ward RA, Greene T, Hartman B, Samtleben W: Resistance to intercompartmental mass transfer limits beta2-microglobulin removed by post-dilution hemodiafiltration. Kidney Int 69 : 1431 –1437, 2006
24. Bradwell AR: Serum Free Light Chain Analysis, 4th Ed., Birmingham, U.K., The Binding Site Ltd., 2006 , pp 104 –107
25. Curtis AR, Sweetenham WP: FACSIMILE/CHECKMATE Users Manual. Rep. AERER 12805, Her Majesty’s Stn. Off., Norwich, UK, 1987
26. Solomon A: Light chains of human immunoglobins. Methods Enzymol 116 : 101 –121, 1985
27. Morgera S, Haase M, Rocktaschel J, Bohler T, von Heymann C, Vergas-Hein O, Krausch D, Zuckermann-Becker H, Mu[Combining Diaeresis]ller JM, Kox WJ, Neumayer HH: High permeability haemofiltration improves peripheral blood mononuclear cell proliferation in septic patients with acute renal failure. Nephrol Dial Transplant 18 : 2570 –2576, 2003
28. Naka T, Jones D, Baldwin I, Fealy N, Bates S, Goehl H, Morgera S, Neumayer HH, Belomo R: Myoglobin clearance by super high-flux hemofiltration in a case of severe rhabdomyolysis: A case report. Crit Care 9 : 90 –95, 2005
29. Torra R, Blade J, Cases A, Lopez-Pedret J, Montserrat E, Rozman C, Revert L: Patients with multiple myeloma requiring long-term dialysis: Presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol 91 : 854 –859, 1995
30. Cserti C, Haspel R, Stowell C, Dzik W: Light chain removal by plasmapheresis in myeloma-associated renal failure. Transfusion 2007 , in press
31. Oakervee HE, Popat R, Curry N, Smith P, Morris C, Drake M, Agrawal S, Stec J, Schenkein D, Esseltine D-L, Cavenagh JD: PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 129 : 755 –762, 2005
32. Tauro S, Clark FJ, Duncan N, Lipkin G, Richards N, Mahendra P: Recovery of renal function after autologous stem cell transplantation in myeloma patients with end-stage renal failure. Bone Marrow Transplant 30 : 471 –473, 2002
33. Mead GP, Carr-Smith HD, Drayson MT, Morgan GT, Child JA, Bradwell AR: Serum free light chains for monitoring multiple myeloma. Br J Haematol 126 : 348 –354, 2004
34. Pratt G, Mead GP, Godfrey KR, Ying H, Evans ND, Chappell MJ, Lovell R, Bradwell AR: The tumor kinetics of multiple myeloma following autologous stem cell transplantation as assessed by measuring serum free light chains. Leuk Lymphoma 47 : 21 –28, 2006